Evaluating Future Steps for Investigating Seleno-L-Methionine in RCC
Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.
Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center, discusses the next steps after the phase 1 trial (NCT02535533) of seleno-L-methionine (SLM) in combination with axitinib (Inlyta) as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC).
Zakharia says that 1 of the observations they had while investigating this clinical trial was that the higher the blood concentration was with SLM, the better response patients had. Although this was a small cohort of patients, the investigators amended the protocol in the study to allow patients with ccRCC to be treated based on their body surface area, and this topic is still ongoing among the authors.
If they continue to see efficacy in the phase 1 data, the next step will be to start a randomized clinical trial of axitinib as the standard of care and the combination of axitinib and SLM in patients with advanced metastatic ccRCC, according to Zakharia.
<< View more resources and information regarding renal cell carcinoma
Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens
November 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.
Read More
Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment
November 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Key Efficacy and Tolerability Factors for Later-Line Therapies in RCC
November 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, and participants discussed issues related to the use of tivozanib and lenvatinib/everolimus as third-line therapies for patients with advanced renal cell carcinoma.
Read More
